Protagenic Therapeutics, Inc. (PTIX) Stock
Healthcare · Biotechnology · US
$0.26
+30.00%
Last updated Aug 3, 2026 04:27 UTC
PTIX Key Statistics
Market Cap$503,068.02
P/E (TTM)-0.08
P/S (TTM)—
P/B (TTM)-0.11
Revenue (TTM)$0.00
EPS (TTM)$-3.45
Dividend Yield—
ROE (TTM)184.88%
Net Margin0.00%
Gross Margin0.00%
52W High$1.20
52W Low$0.17
Analyst ViewBuy
Price Target—
Employees1
Volume3,032
About Protagenic Therapeutics, Inc.
Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company is based in New York, New York.
CEO: Garo H. Armen. Company website
See PTIX live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open PTIX in Terminal See plans